Healthcare - Cancer Research

Watchlist

Cancer research includes companies engaged in scientific research on the causes, prevention, diagnosis, treatment, and potential cures for cancer. It involves many disciplines, from biology and genetics to clinical trials and drug development. These companies produce life-saving products for a rapidly growing and highly sought-after market and form strategic partnerships with global organizations. This makes them appealing to investors seeking both financial gain and support for healthcare advancements and patient outcomes.

  • 999.825
  • -0.572-0.06%
20min DelayMarket Closed Jan 23 16:00 AET
1007.220High998.228Low
Intraday
  • 5D
  • Daily
  • Weekly
  • Monthly
  • 1Q
  • 1Y
Constituent Stocks
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
WatchlistPaper Trade
IMMImmutep Ltd
0.3300.005+1.54%1.31M431.55K0.3300.3250.3350.325480.01M413.14M1.45B1.25B+1.54%0.00%-2.94%+10.00%+11.86%-1.49%-9.59%--0.11%0.00Loss3.08%Biotechnology
MSBMesoblast Ltd
2.7700.020+0.73%9.83M27.19M2.7902.7502.8302.7203.20B2.11B1.16B763.05M+1.47%-9.18%-9.18%+114.73%+178.39%+945.28%-10.65%--1.29%0.00Loss4.00%Biotechnology
TLXTelix Pharmaceuticals Ltd
26.8900.050+0.19%1.16M31.10M26.87026.84027.29026.7209.00B7.60B334.72M282.77M+4.22%+10.89%+9.22%+25.30%+53.48%+133.83%+9.26%--0.41%180.471680.632.12%Biotechnology
CSLCSL Ltd
270.000-0.250-0.09%737.31K199.35M272.500270.250272.500269.500130.74B130.67B484.21M483.95M-2.04%-6.10%-2.92%-7.53%-9.67%-7.76%-4.11%1.37%0.15%33.0433.041.11%Biotechnology
CUVClinuvel Pharmaceuticals Ltd
11.690-0.020-0.17%90.64K1.06M11.75011.71011.79011.620585.21M483.61M50.06M41.37M-0.85%+2.01%-3.47%-19.38%-14.20%-24.09%-3.07%0.43%0.22%16.7516.751.45%Biotechnology
IMUImugene Ltd
0.038-0.001-2.56%14.22M546.86K0.0390.0390.0390.038287.56M238.33M7.57B6.27B-2.56%-13.64%+2.70%-20.83%-25.49%-63.81%+2.70%--0.23%LossLoss2.56%Biotechnology

News

Comments

Read more